U.S. pharma large copyright scrapped two experimental weight loss capsules previous 12 months—a as soon as-daily tablet, lotiglipron, because of elevated liver enzymes and a twice-daily pill, danuglipron, resulting from potent Unwanted effects—but CEO Albert Bourla has said the company is determined to “Engage in and acquire” from the being